title: Monocyte chemotactic protein-1 expression as a prognosic biomarker in patients with solid tumor: a meta analysis.
abstract: OBJECTIVE
  A great deal of studies have been performed on the prognostic value of monocyte chemotactic protein-1 (MCP-1) in solid tumors in recent years. However, no consistent outcomes are reported. Therefore, the prognostic value of MCP-1 still remains controversial in patients with solid tumors. Here we aimed to evaluate the prognostic value of MCP-1 expression for patients with solid tumors.
  
  
  METHODS
  Comprehensive literature was selected from PUBMED and EMBASE and clinical studies which reported analysis of survival data about MCP-1 in solid tumors were included. Stata 11.0 was used for performing a meta-analysis on evaluating the relation between MCP-1 and clinical staging, overall survival (OS) and disease free survival (DFS).
  
  
  RESULTS
  Eleven studies with a total of 1324 patients with solid tumors were included into our meta-analysis. The result showed that high concentration of MCP-1 was related to a worse OS (HR = 1.95, 95% CI 1.32-2.88). The subgroup analysis on different location of tumors showed that high concentration of MCP-1 meant bad prognosis in patients with digestive cancer (HR = 2.66, 95% CI 1.44-4.91) and urogenital cancer (HR = 2.23, 95% CI 1.61-3.10), even head and neck cancer (HR = 1.99, 95% CI 0.95-4.18) other than respiratory cancer (HR = 1.10, 95% CI 0.39-3.11). Another subgroup analysed on different sites of cancer and indicated a poor prognosis on adenocarcinoma (HR = 2.10, 95% CI 1.63-2.69).
  
  
  CONCLUSIONS
  Our findings suggest that MCP-1 can be regarded as a poor prognostic maker for solid tumors and may represent important new therapeutic targets.
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Qiongwen
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Hongyu
authors.initials: H
authors.lastname: Kong
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Yunhui
authors.initials: Y
authors.lastname: Zeng
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Meiqin
authors.initials: M
authors.lastname: Hao
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Ting
authors.initials: T
authors.lastname: Yu
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Peng
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Zhao
authors.initials: Z
authors.lastname: Xu
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Jingquan
authors.initials: J
authors.lastname: Chen
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China School of Medicine/West China Hospital, Sichuan University Chengdu, Sichuan Province, P.R. China.
authors.forename: Huashan
authors.initials: H
authors.lastname: Shi
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D018932:Chemokine CCL2 / Q000032:analysis / Q000096:biosynthesis*; D018572:Disease-Free Survival; D006801:Humans; D009369:Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C111835:CCL2 protein, human; D018932:Chemokine CCL2
keywords: Monocyte chemotactic protein-1; cancer; meta-analysis; overall survival; prognosis